(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Eugene Shenderov presented preliminary results of a phase I cohort expansion testing MGC018, an investigational ADC with a duocarmycin payload linked to an anti-B7-H3 monoclonal antibody, in patients with metastatic castration resistant prostate cancer (mCRPC).